Journal article · 2007 · Open access

Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling

Lisa J. Frederiksen, Richard Sullivan, Lori Maxwell, Shannyn K. Macdonald-Goodfellow, MICHAEL A. ADAMS, Brian M. Bennett, David Robert Siemens, Charles H. Graham

Clinical Cancer Research, 13(7), 2199–2206 · Published 1 April 2007 · DOI 10.1158/1078-0432.ccr-06-1807

Open PDFView at the publisherCite this paper

In brief

“Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling” is a 2007 journal article by Lisa J. Frederiksen and 7 co-authors, published in Clinical Cancer Research. OpenAlex counts 141 citations as of 19 November 2026, which puts it in the top 7% of works published in 2007 by citations. It is open access: the full text is free to read at Clinical Cancer Research.

Citations
141
Most cited in
2021 (12)
Field-weighted impact
2.66
References
41
Authors
8

Abstract

PURPOSE: Hypoxia contributes to drug resistance in solid cancers, and studies have revealed that low concentrations of nitric oxide (NO) mimetics attenuate hypoxia-induced drug resistance in tumor cells in vitro. Classic NO signaling involves activation of soluble guanylyl cyclase, generation of cyclic GMP (cGMP), and activation of cGMP-dependent protein kinase. Here, we determined whether chemosensitization by NO mimetics requires cGMP-dependent signaling and whether low concentrations of NO mimetics can chemosensitize tumors in vivo. EXPERIMENTAL DESIGN: Survival of human prostate and breast cancer cells was assessed by clonogenic assays following exposure to chemotherapeutic agents. The effect of NO mimetics on tumor chemosensitivity in vivo was determined using a mouse xenograft model of human prostate cancer. Drug efflux in vitro was assessed by measuring intracellular doxorubicin-associated fluorescence. RESULTS: Low concentrations of the NO mimetics glyceryl trinitrate (GTN) and isosorbide dinitrate attenuated hypoxia-induced resistance to doxorubicin and paclitaxel. Similar to hypoxia-induced drug resistance, inhibition of various components of the NO signaling pathway increased resistance to doxorubicin, whereas activation of the pathway with 8-bromo-cGMP attenuated hypoxia-induced resistance. Drug efflux was unaffected by hypoxia and inhibitors of drug efflux did not significantly attenuate hypoxia-induced chemoresistance. Compared with mice treated with doxorubicin alone, tumor growth was decreased in mice treated with doxorubicin and a transdermal GTN patch. The presence of GTN and GTN metabolites in plasma samples was confirmed by gas chromatography. CONCLUSION: Tumor hypoxia induces resistance to anticancer drugs by interfering with endogenous NO signaling and reactivation of NO signaling represents a novel approach to enhance chemotherapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Frederiksen, L. J., Sullivan, R., Maxwell, L., Macdonald-Goodfellow, S. K., ADAMS, M. A., Bennett, B. M., Siemens, D. R., & Graham, C. H. (2007). Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling. Clinical Cancer Research, 13(7), 2199–2206. https://doi.org/10.1158/1078-0432.ccr-06-1807

MLA 9

Frederiksen, Lisa J., et al. “Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling.” Clinical Cancer Research, vol. 13, no. 7, 2007, pp. 2199–2206. https://doi.org/10.1158/1078-0432.ccr-06-1807.

Chicago

Frederiksen, Lisa J., Richard Sullivan, Lori Maxwell, Shannyn K. Macdonald-Goodfellow, MICHAEL A. ADAMS, Brian M. Bennett, David Robert Siemens, and Charles H. Graham. 2007. “Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling.” Clinical Cancer Research 13 (7): 2199–2206. https://doi.org/10.1158/1078-0432.ccr-06-1807.

Harvard

Frederiksen, L. J. et al. (2007) ‘Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling’, Clinical Cancer Research, 13(7), pp. 2199–2206. doi:10.1158/1078-0432.ccr-06-1807.

IEEE

L. J. Frederiksen et al., “Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling,” Clinical Cancer Research, vol. 13, no. 7, pp. 2199–2206, 2007, doi: 10.1158/1078-0432.ccr-06-1807.

BibTeX

@article{frederiksen2007chemosensitization,
  title     = {{Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling}},
  author    = {Frederiksen, Lisa J. and Sullivan, Richard and Maxwell, Lori and Macdonald-Goodfellow, Shannyn K. and ADAMS, MICHAEL A. and Bennett, Brian M. and Siemens, David Robert and Graham, Charles H.},
  journal   = {Clinical Cancer Research},
  year      = {2007},
  volume    = {13},
  number    = {7},
  pages     = {2199--2206},
  doi       = {10.1158/1078-0432.ccr-06-1807},
  url       = {https://doi.org/10.1158/1078-0432.ccr-06-1807}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20171010
201866
20191010
20201111
20211212
202266
202388
202422
202522
202622

Its field-weighted citation impact is 2.66: it has been cited 2.66 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism

  • nitric oxide signaling
  • chemosensitization
  • tumor hypoxia
  • drug resistance
  • doxorubicin
  • paclitaxel
  • nitroglycerin
  • isosorbide dinitrate

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Frederiksen, L. J., Sullivan, R., Maxwell, L., Macdonald-Goodfellow, S. K., ADAMS, M. A., Bennett, B. M., Siemens, D. R., & Graham, C. H. (2007). Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling. Clinical Cancer Research, 13(7), 2199–2206. https://doi.org/10.1158/1078-0432.ccr-06-1807

How many times has this paper been cited?

141 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Cancer Research: sign in and open the PDF from this page.

Who wrote this paper?

Lisa J. Frederiksen, Richard Sullivan, Lori Maxwell, Shannyn K. Macdonald-Goodfellow, MICHAEL A. ADAMS, Brian M. Bennett, David Robert Siemens, Charles H. Graham.

What is the DOI of this paper?

10.1158/1078-0432.ccr-06-1807, permanently at https://doi.org/10.1158/1078-0432.ccr-06-1807. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.